

Atty. Docket No. PU3517USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Clarence Webster ANDREWS III et al.

Serial No.: 10/070,084

Art Unit: 1624

Filing Date: March 7, 2002

Examiner: Rao, Deepak

For: *Benzophenones as Inhibitors of Reverse Transcriptase*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed.
☐ Copies of the references were submitted in parent application Serial No. _____
(37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☒ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted to (571) 273-8300 on December 22, 2005.


Patty Wilson

BEST AVAILABLE COPY

Atty. Docket No. PU3517USw

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.☒ A duplicate copy of this paper is attached.

Respectfully Submitted,



Kimberly H. Parker
Attorney of Record
Registration No. 47,843

Date: December 22, 2005
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8406
Facsimile: (919) 483-7988

BEST AVAILABLE COPY

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO.		10/070,084			
		FILING DATE		March 7, 2002			
		APPLICANT		Andrews III et al.			
		GROUP		1624			
		EXAMINER		Rao, Deepak			
		ATTORNEY DOCKET NO.		PU3517USw			
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
							Yes
Continue on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	1.	http://www.hivguidelines.org/public_html/center/clinical-education/q-and-a/hiv-2.htm					
	2.	http://www.aegis.com/aidsline/1992/nov/M92B0027.html					
Continue on page							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

BEST AVAILABLE COPY

Atty. Docket No. PU3517USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Clarence Webster ANDREWS III et al.

Serial No.: 10/070,084

Art Unit: 1624

Filing Date: March 7, 2002

Examiner: Rao, Deepak

For: *Benzophenones as Inhibitors of Reverse Transcriptase*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed.

☐ Copies of the references were submitted in parent application Serial No. _____
(37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).


OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☒ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted to (571) 273-8300 on December 22, 2005.


Patty Wilson

BEST AVAILABLE COPY


Atty. Docket No. PU3517USw

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☒ A duplicate copy of this paper is attached.

Respectfully Submitted,



Kimberly H. Parker
Attorney of Record
Registration No. 47,843

Date: December 22, 2005
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8406
Facsimile: (919) 483-7988

BEST AVAILABLE COPY

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO.		10/070,084			
		FILING DATE		March 7, 2002			
		APPLICANT		Andrews III et al.			
		GROUP		1624			
		EXAMINER		Rao, Deepak			
		ATTORNEY DOCKET NO.		PU3517USw			
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
							Yes
Continue on page							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	1.	http://www.hivguidelines.org/public_html/center/clinical-education/q-and-a/hiv-2.htm					
	2.	http://www.aegis.com/aidsline/1992/nov/M92B0027.html					
Continue on page							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

BEST AVAILABLE COPY